Tumor Suppressing Viruses, Genes, and Drugs profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.


Oncologists, cancer researchers, geneticists, and pharmaceutical researchers.

Table of Contents

Contributors Preface 1 Oncolytic Viruses: Virotherapy for Cancer I. Introduction II. Attributes of Replication-Selective Viruses for Cancer Treatment III. Approaches to Optimizing Tumor-Selective Viral Replication IV. Adenoviruses V. Poliovirus VI. Vesicular Stomatitis Virus VII. Reovirus VIII. Bacteria IX. Vaccinia Virus X. Herpesvirus XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042) XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents XIV. Summary References 2 Reovirus Therapy of Ras-Associated Cancers I. Introduction II. Reovirus Oncolysis III. Concluding Remarks References 3 Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical I. Introduction II. Preclinical Studies of G207 III. G207 Clinical Trial IV. Conclusions References 4 p53 and Its Targets I. Introduction II. Activation of p53 III. Downstream Mediators of p53 References 5 Prospects for Tumor Suppressor Gene Therapy: RB as an Example I. Introduction II. Functions of RB III. Successes with RB Gene Therapy IV. Perspectives References 6 CDK Inhibitors: Genes and Drugs I. Introduction II. G1 Regulation III. p16INK4a and the Rb Pathway IV. p19ARF and p53 Pathway V. p27 and Human Cancer VI. Conclusions and Future Perspectives References 7 CDK Inhibitors: Small Molecular Weight Compounds I. Introduction II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures IV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem VI. Cyclin-De


No. of pages:
© 2002
Academic Press
eBook ISBN:
Print ISBN:
Print ISBN:

About the editor

Hiroshi Maruta

Affiliations and Expertise

Ludwig Institute for Cancer Research, Victoria, Australia


"...a brave attempt to encompass a broad, exciting and developing field." -MICROBIOLOGY TODAY (2003)